Search Results
Your search for ,maY matches 16983 pages
Showing 11551 - 11600Precision Medicine Clinical Trial for Metastatic Pancreatic Cancer Now Open at Multiple Sites
The first clinical trial to compare standard-of-care chemotherapy with molecularly tailored therapy (also known as precision medicine) for metastatic pancreatic cancer is now enrolling patients at multiple sites around the country. Patients who have been treated with one round of chemotherapy for...
Four-Biomarker Panel Identified for Chronic Graft-vs-Host Disease
In a study reported in the Journal of Clinical Oncology, Jeffrey Yu, MD, of the Indiana University School of Medicine, Indianapolis, and colleagues identified a four-biomarker panel that was predictive of chronic graft-vs-host disease after allogeneic hematopoietic cell transplantation. Discovery...
Increased Risk of Gallbladder Cancer May Be Associated With Consuming Large Amounts of Sweetened Beverages
A large prospective Swedish study reported by Susanna C. Larsson, PhD, of the Unit of Nutritional Epidemiology at the Institute of Environmental Medicine at Karolinska Institutet in Stockholm, Sweden, and colleagues found a 2.2-fold increased risk of gallbladder cancer in people who consumed two or ...
Adding Adjuvant Oxaliplatin to Fluoropyrimidine May Be of Benefit in Deficient Mismatch Repair Colon Cancer
In a French retrospective study reported by David Tougeron, MD, PhD, of Poitiers University Hospital, Poitiers, France, and colleagues in the Journal of the National Cancer Institute, the addition of adjuvant oxaliplatin to fluoropyrimidine treatment improved disease-free survival in patients with...
Retroviral Replicating Vector That Delivers Cytosine Deaminase to Cancer Cells Active in Recurrent Glioblastoma
A phase I study by Timothy F. Cloughesy, MD, Director of the Neuro-Oncology Program at the UCLA Jonsson Comprehensive Cancer Center, and colleagues published in Science Translational Medicine investigated the effectiveness of vocimagene amiretrorepvec (Toca 511), an experimental nonlytic,...
Use Questions From Patients to Help Them Make Informed Treatment Decisions
Recent reports about treatment options for patients with ductal carcinoma in situ, and the ensuing debate and comments played out in the media, may prompt increased questions from patients. A review summarizing data about these treatment options concluded that surgery and radiation therapy “remain...
Surgery and Radiation Therapy Remain Standard of Care for Managing Ductal Carcinoma in Situ
A review of more than 50 studies (many randomized controlled trials) concluded that surgery and radiation therapy “remain standard-of-care treatment options” in the management of ductal carcinoma in situ.1 The review continues the widely reported discussion on managing ductal carcinoma in situ,...
Black Cohosh
Scientific Name: Cimicifuga racemosa Common Names: Black snakeroot, rattlesnake root, squawroot, bugbane, bugwort Brand Names: Remifemin, Menofem, Klimadynon Overview A perennial plant native to the eastern United States and Canada, black cohosh root was used by Native Americans to treat colds,...
Moonshot Program for … Compassion
A 65-year-old patient with widely metastatic pancreatic cancer was emergently transferred to our facility in the early hours of the morning with free air suggestive of a perforated viscus. The patient is from a small town several hundred miles away from our academic center, which can be quite...
Clinical Trials Actively Recruiting Patients With Ocular Cancer
Phase 0 Study Title: Use of Definity® Contrast Agent for Ultrasound of Intraocular Tumors Study Type: Interventional/single-group assignment Study Sponsor and Collaborators: Emory University Purpose: To determine if microbubbles may be used as a contrast agent to help image tumors in the eye. In...
Vanguard Practices Support Sharing Big Data With CancerLinQ™
CancerLinQ LLC, recently announced that it has completed agreements with 36 vanguard oncology practices from around the country to begin implementing the tool. According to physicians at the vanguard practices, gaining access to the experience of oncology practices across the country motivated...
Initiative to Modernize Eligibility Criteria for Clinical Trials Launched
ASCO and Friends of Cancer Research (Friends) have launched a collaborative effort to modernize eligibility criteria to promote greater patient participation in cancer clinical trials. Although it is important for defining the population under study and ensuring patient safety, overly strict...
Clinical Conversations: Attendee Questions From the Cancer Survivorship Symposium
The inaugural Cancer Survivorship Symposium, held in January 2016, drew more than 800 attendees across the cancer-care spectrum—far exceeding the goal of 500 attendees. As a way to continue the discussion from the meeting, several faculty members responded to questions from General Sessions 5 and...
Erratum
In the June 10 issue of The ASCO Post, the article "Anti–PD-1 Inhibitor Gains Foothold in Merkel Cell Carcinoma," a photo labeled Paul Nghiem, MD, PhD, is incorrect. The photo that was printed is Paul Nguyen, MD, of the Dana-Farber Cancer Institute. A photo of Dr. Nghiem is shown here. Dr. Nghiem ...
Geriatric Patients With Cancer and the Problem of Polypharmacy
Older patients with cancer generally have multiple comorbidities, with each often requiring separate medications. Studies have shown that polypharmacy and inappropriate drug use are prevalent among older cancer patients, leading to an enormous amount of preventable adverse events, many requiring...
Pembrolizumab in Triple-Negative Breast Cancer: Emerging New Treatment Modality
Lajos Pusztai, MD, DPhil, Professor of Medicine, Chief of Breast Medical Oncology and Co-Director of Cancer Genetics Research Program at Yale Cancer Center, New Haven, Connecticut, commented on KEYNOTE-012. He remarked that the overall response rate of 18.5% to the single agent is similar to...
Anti–PD-1 Treatment With Pembrolizumab in Gastric/Gastroesophageal Junction Cancers: Who Is Likely to Respond?
Immune checkpoint inhibitors have emerged as one of the most promising new areas of drug development in oncology. Broad activity has been observed for these agents across a spectrum of hematologic malignancies and solid tumors. As reviewed in this issue of The ASCO Post, Muro and colleagues now...
Nivolumab or Ipilimumab Treatment May Increase Risk of Developing Autoimmune Joint and Tissue Disease
Case reports on 13 patients with cancer suggest that patients taking the immunotherapeutics ipilimumab (Yervoy) and nivolumab (Opdivo) may be at higher-than-normal risk of developing autoimmune joint and tissue diseases, including inflammatory arthritis, according to a preliminary study by Johns...
Hypofractionated Radiation Found Equivalent to Conventionally Fractionated Regimen in Early-Stage Breast Cancer
Early-stage breast cancer patients receiving a shorter course of whole-breast irradiation with higher radiation doses per fraction reported equivalent cosmetic, functional, and pain outcomes over time as those receiving a longer, lower-dose per fraction course of treatment, according to researchers ...
Pembrolizumab Active in PD-L1–Positive Advanced Gastric Cancer and Triple-Negative Breast Cancer
The KEYNOTE-012 phase Ib trial assessed single-agent pembrolizumab (Keytruda) in patients with advanced programmed cell death ligand 1 (PD-L1)–positive gastric cancer, triple-negative breast cancer, urothelial cancer, and head and neck cancer. The activity of pembrolizumab in study patients with...
Three Leaders in Radiation Oncology Awarded the ASTRO Gold Medal
Three leaders in radiation oncology have been named recipients of the American Society for Radiation Oncology (ASTRO) Gold Medal. Benedick A. Fraass, PhD, FASTRO; Christopher G. Willett, MD, FASTRO; and Anthony L. Zietman, MD, FASTRO; will be recognized at an awards ceremony during ASTRO’s 58th...
Guidelines to Assess and Manage the Symptoms of Fatigue and Insomnia
In 2014, ASCO developed a clinical practice guideline to provide a mechanism for physicians to screen, assess, and manage the persistent symptoms of fatigue in adult cancer survivors.1 As summarized below, the guideline calls for regular screening, assessment, laboratory evaluation, and patient...
Tackling the Symptoms of Long-Term Fatigue and Insomnia in Cancer Survivors
Fatigue and sleep disruption are common occurrences for most patients diagnosed with cancer. Simply having a serious physical illness like cancer along with its associated pain, hospitalization, and treatment, as well as the attendant psychological impact, all contribute to the onset of fatigue...
A Conquer Cancer Foundation Award Helps to Launch a Pioneering Study in Liposarcoma
Mark A. Dickson, MD, has been fascinated by science and medicine since he was in high school. After graduating magna cum laude from Harvard University in 1999, Dr. Dickson pursued a medical degree from the College of Physicians and Surgeons at Columbia University in New York. Once he decided on a...
Adherence to Cancer Prevention Guidelines on Diet and Physical Activity May Reduce Cancer Risk and Mortality
According to the American Cancer Society’s 2016 Cancer Facts & Figures, behaviors such as poor diet choices, physical inactivity, excess alcohol consumption, and unhealthy body weight account for about 20% of all cancers diagnosed in the United States and likely could be prevented with...
Ixazomib: A Relevant Addition to Myeloma Therapy
In 2015, four new drugs were approved for the treatment of multiple myeloma by the U.S. Food and Drug Administration: panobinostat (Farydak), daratumumab (Darzalex), elotuzumab (Empliciti), and ixazomib (Ninlaro). Of them, the first three are drugs with unique new targets, whereas ixazomib is the...
Addition of Ixazomib to Lenalidomide/Dexamethasone Improves Progression-Free Survival in Relapsed/Refractory Multiple Myeloma
In the phase III TOURMALINE-MM-1 trial reported in The New England Journal of Medicine, Philippe Moreau, MD, of the University Hospital Hôtel Dieu, Nantes, France, and colleagues found that adding the oral proteasome inhibitor ixazomib (Ninlaro) to lenalidomide (Revlimid) and dexamethasone...
Medical Decision-Making: At the Heart of Care for Older Patients With Cancer
Although oncology has moved toward a personalized approach to care, medical decision-making within the context of multidisciplinary care has broad public health implications. To shed light on this and other relevant issues, The ASCO Post recently spoke with William Dale, MD, PhD, of the University ...
Updated WHO Classification of Hematologic Malignancies
Question 1: Which statement about the classification of tumors of hematopoietic and lymphoid tissues is true? Correct Answer: A. The revised WHO classification defines distant disease entities that can be reliably diagnosed using proposed criteria. Expert Perspective WHO last updated its...
Treatment Update in Gastric, Pancreatic, and Colorectal Cancers
Although new gastrointestinal cancers are on the rise, advancements in their treatment, as well as the upcoming results of perioperative trials, could prove to be “clinical practice game-changers,” declared Thomas J. George, Jr, MD, FACP, at the 2016 Community Oncology Conference in Orlando,...
Expert Point of View: Samir Gupta, MD
Samir Gupta, MD, Associate Professor of Medicine at the University of California San Diego, who has led trials of colorectal cancer screening, commented on this study for The ASCO Post. Although there are approximately 138,000 new colorectal cancer diagnoses a year in the United States, only...
Young-Onset Colorectal Cancer Diagnoses Rising
Colorectal cancer is being increasingly diagnosed in persons younger than age 50, the age at which colorectal cancer screening is usually initiated. According to Elie Sutton, MD, of Mount Sinai West Hospital in New York, a review of cases in the National Cancer Data Base revealed that between...
Impressive Early Data for Rovalpituzumab Tesirine in Small Cell Lung Cancer
Initial encouraging news from a first-in-human trial suggests that the antibody-drug conjugate rovalpituzumab tesirine (Rova-T) may turn out to be a new option for patients with small cell lung cancer (SCLC) whose tumors overexpress delta-like protein 3 (DLL3). Study results were presented at the...
Expert Point of View: Peter C. Enzinger, MD
Not so FAST? The study discussant Peter C. Enzinger, MD, Director of the Center for Esophageal and Gastric Cancer at Dana-Farber/Brigham and Women’s Cancer Center, Boston, viewed the findings of the FAST trial as promising but voiced several considerations, as did Gulam A. Manji, MD, PhD,...
Expert Point of View: Sumanta K. Pal, MD, and Richard L. Schilsky, MD
“This study harnesses a specific biologic marker in cancer patients and treats them accordingly using a ‘tumor-agnostic’ approach, so a patient with pancreatic cancer may get a breast cancer drug,” said Sumanta K. Pal, MD, ASCO spokesperson. Dr. Pal moderated the press conference where these data ...
Vast Differences Globally in Cancer Drug Retail Prices
A pilot study revealed large differences in median retail prices for 23 cancer drugs in 7 different countries, with the highest retail prices identified in the United States and the lowest, in India and South Africa. Notably, after the monthly drug price is expressed as a percentage of domestic...
CAR T-Cell Therapy Using Double Target Aimed at Solid Tumors in Preclinical Models
Chimeric antigen receptors (CARs), engineered from a patient's own immune cells, have been successful for treating blood cancers, but using CARs for solid tumors has been limited by side effects to normal tissues containing the protein targeted by the engineered cells. Now, in a report published...
Influence of Age and Comorbidities on Rates of Colorectal Cancer Screening in the Elderly
Colorectal cancer (CRC) is a common and costly disease, largely of the elderly, with nearly 25% of cases diagnosed among patients aged 75–84 years. However, but the guidelines for CRC screening of Americans aged 75 or older vary according to the source. In a study published by Klabunde et al...
Aggressive Treatment at the End of Life Continues to Be Common
Oncologists in the United States may need to improve their efforts to reduce unnecessary care for younger patients with terminal cancer over the last 30 days of life, based on the findings of a study reported at the 2016 ASCO Annual Meeting.1 Contrary to recommendations, aggressive care is still...
Expert Point of View: Don Dizon, MD
Don Dizon, MD, Chair of ASCO’s Cancer Communications Committee, congratulated the authors of the OV21/PETROC study. “This is another example of international collaboration. The authors looked at the role of IP therapy in women who got primary chemotherapy before surgery, and at least in this...
ASCO Releases the Updated Version of Its Value Framework
Last June, ASCO published its initial concept for a value framework in the Journal of Clinical Oncology (JCO).1 The framework, developed by ASCO’s Value in Cancer Care Task Force, is designed to provide a standardized approach to assist physicians and patients in assessing the “value” of a new...
Expert Point of View: Dominique Valteau-Couanet, MD, PhD
Study discussant Dominique Valteau-Couanet, MD, PhD, of the Gustave Roussy in France, said the study was “an important step” in research, by showing “Cy-THIO/mCEM [tandem autologous stem cell transplant (ASCT) with cyclophosphamide/thiotepa followed by a modified regimen of...
For High-Risk Neuroblastoma, Two Transplants May Be Better Than One
In children with high-risk neuroblastoma, tandem autologous stem cell transplant (ASCT) improved event-free survival rates in the ANBL0532 trial from the Children’s Oncology Group. The study was presented at the plenary session of the 2016 ASCO Annual Meeting by Julie R. Park, MD, of Seattle...
Low-Dose CT Screening May Detect New Solid Nodules and Lung Cancer Probability
As reported by Walter et al in The Lancet Oncology, incidence screening with low-dose computed tomography (CT) in high-risk individuals detected new solid nodules in approximately 5% to 7% at second and third screenings in the ongoing Dutch-Belgian NELSON trial. Larger nodule size was associated...
Patient Navigators Improve Comprehensive Cancer Center Screening Rates
A clinical trial conducted by Massachusetts General Hospital (MGH) investigators has found that the use of patient navigators—individuals who assist patients in receiving health care services—may improve comprehensive cancer screening rates among patient populations not likely to...
Report Finds Families of Cancer Survivors Challenged by Intense, Episodic Caregiving Experiences
A new report shows that people caring for a loved one with cancer often have more intense, episodic caregiver responsibilities than those caring for someone with other health needs. The report, from the National Alliance for Caregiving in partnership with the National Cancer Institute and the...
SNMMI 2016: VASH Collimator Allows Three-Dimensional Imaging of the Breast With Less Radiation
Preliminary tests have demonstrated that a new device may enable existing breast cancer imagers to provide up to six times better contrast of tumors in the breast, while maintaining the same or better image quality and halving the radiation dose to patients. The advance is made possible by a new...
SNMMI 2016: PET/CT Imaging of Prostate Cancer With Specific Agent May Be an Accurate Prebiopsy/Preoperative Guide
With surgical removal at the frontline of defense against prostate cancer, oncologists are considering prostate-specific molecular imaging at the point of initial biopsy and preoperative planning to root out the full extent of disease, researchers showed at the 2016 Annual Meeting of the Society of ...
Lifestyle Pattern May Be Associated With Cancer Risk in White Adults
In a study reported in JAMA Oncology, Song and Giovannucci found that a “healthy lifestyle pattern” was associated with a reduced risk for carcinomas among white adults. Study Details The study included data from the Nurses’ Health Study and the Health Professionals Follow-up...
Neoadjuvant Chemotherapy May Render Advanced Ovarian Cancers Responsive to Immunotherapy
Although most patients with advanced ovarian cancer initially respond to platinum-based chemotherapy, they usually relapse. According to a study by Böhm et al published in Clinical Cancer Research, neoadjuvant chemotherapy seemed to alter the immune cells in the tumors of patients with...
